| DOI | Resolve DOI: https://doi.org/10.1016/0014-5793(86)80877-8 |
|---|
| Author | Search for: Ingold, K. U.1; Search for: Burton, G.W.1; Search for: Foster, D.O.1; Search for: Zuker, M.1; Search for: Hughes, L.1; Search for: Lacelle, S.1; Search for: Lusztyk, E.1; Search for: Slaby, M.1 |
|---|
| Affiliation | - National Research Council of Canada
|
|---|
| Format | Text, Article |
|---|
| Subject | 3,4 dihydro 5 hydroxy 2,4,6,7 tetramethyl 2 (4,8,12 trimethyltridecyl)benzofuran acetate; alpha tocopherol; pyruvate kinase; unclassified drug; animal experiment; biological model; blood and hemopoietic system; drug comparison; drug screening; drug synthesis; muscle; muscle disease; oral drug administration; rat; Diet; Kinetics; Male; Muscles; Pyruvate Kinase; Rats; Rats, Inbred Strains; Stereoisomerism; Vitamin E; Vitamin E Deficiency; Animalia |
|---|
| Abstract | Vitamin E owes its biological effects to its antioxidant activity. Kinetic and mechanistic studies on phenolic antioxidants in vitro have led us to design and synthesize all-rac-2,4,6,7-tetramethyl-2-(4',8',12'-trimethyltridecyl)-5-hydroxy-3,4-dihydrobenzofuran, 3. In the rat curative myopathy bioassay the acetate of this compound has 1.5-1.9 times the bioactivity of all-rac-α-tocopherol acetate. This represents the first time that a rationally designed synthetic 'vitamin' has been found to have more activity in vivo than the corresponding natural vitamin. © 1986. |
|---|
| Publication date | 1986 |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| NPARC number | 21276632 |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | 4bd2bb40-bfa9-495b-addd-74508add7b3d |
|---|
| Record created | 2015-10-13 |
|---|
| Record modified | 2020-03-17 |
|---|
